Angel Biotechnology Holdings Plc Update and Notice of General Meeting (3995U)
28 12월 2012 - 4:00PM
UK Regulatory
TIDMABH
RNS Number : 3995U
Angel Biotechnology Holdings Plc
28 December 2012
28 December 2012
Angel Biotechnology Holdings plc
("Angel" or "the Group")
Update and Notice of General Meeting
Angel Biotechnology Holdings plc, (AIM:ABH), the
biopharmaceutical contract manufacturer, announces that the Group
will hold a General Meeting on Monday 28 January 2013 at 10.30am at
the offices of Angel Biotechnology Holdings plc, 44 Colbourne
Crescent, Cramlington, NE23 1WB. The purpose of this meeting, which
is being called pursuant to section 656 of the Companies Act 2006,
is to consider whether any, and if so what, steps should be taken
in connection with a reduction of net assets. The Notice of General
Meeting and form of proxy will be distributed to shareholders on 31
December 2012 and will be available on the Company's website,
www.angelbio.com.
The Board is pleased to confirm that AB Biotechnology Ltd has
been formed as the company through which our joint venture
partnership with OOO NPF Materia Medica Holding ("MMH") will be
conducted. Angel and Mapix s.a.r.l. (Mapix), an MMH associated
company, will subscribe to AB Biotechnology Ltd on a 40:60 basis
respectively although it is expected that Angel will reduce its
holding in AB Biotechnology Ltd going forward. Final legal review
of the agreements is on-going and formal signature is expected
mid-January when the directors of both partners will be on-site at
Pentlands Science Park. A more detailed announcement of the terms
of the joint venture will be released at that time.
As announced on 12 October 2012, Dr. Paul Harper will step down
from the Board effective 31 December 2012. We would like to
reiterate our thanks to Dr. Harper for his stewardship of the Group
and wish him well for the future.
Mr. Nicholas Smith, Non-Executive Chairman said: "I look forward
to completing the final formalities in order to bring into effect
as AB Biotechnology Ltd the ongoing co-operation with MMH.
Regarding the final completion, both parties have agreed to sign
the final documents in mid-January 2013. The team at Angel will
continue with their focus on long-term strategic discussions which
will rebuild the capital of the rest of the business and we shall
be explaining further our strategy to this end at the forthcoming
General Meeting."
For further information:
Angel Biotechnology Holdings plc
Nicholas Smith, Non-Executive Chairman +44 (0) 131 445 6077
www.angelbio.com
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
Philip Ranger / Caolan Mahon +44 (0) 20 7536 2028 / 2029
Notes to Editors:
Angel Biotechnology Holdings plc is a full service contract
bio-manufacturing partner to biotechnology and pharmaceutical
companies worldwide. Angel specialises in advanced biologics
including biopharmaceutical proteins and cell therapies, such as
cellular vaccines and stem cells. At present, Angel's products are
principally used in pre-clinical studies and clinical trials with a
view to becoming the contract manufacturer of choice on a
continuing basis.
Drug development companies outsource their biopharmaceutical
manufacturing requirements to Angel to reduce their own capital
requirements and enable them to develop products more rapidly. In
addition, Angel provides complete regulatory services and
documentation to its customers while its manufacturing processes
adhere to the most stringent regulatory requirements. Products are
produced to current Good Manufacturing Practice (cGMP) standards as
required by the US Food and Drug Administration (FDA) and in
facilities that are certified to European standards by the
Medicines and Healthcare products Regulatory Agency (MHRA).
Its customers range from pioneering biotechnology companies such
as ReNeuron Group plc to established pharmaceutical companies such
as Russian-based OOO "NPF Materia Medica Holding".
Angel has three facilities: Pentlands Science Park near
Edinburgh, a site in Cramlington, near Newcastle-upon-Tyne and the
Angel Biomedical Ltd facility in Glasgow.
More information is available at www.angelbio.com .
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEDLFLLLFBFBL
Angel Biotechnology (LSE:ABH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Angel Biotechnology (LSE:ABH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
